Stay updated with breaking news from Sam Banister. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Australia biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo (OTCMKTS: DSNKY) toward advancing antidepressant psychiatric medicines.
As the psychedelic medicine gold rush accelerates, there are ways to game the system and some companies are testing the limits of patent law.
Biotechs backed by billionaires Andrew Forrest and Gina Rinehart are racing to get psychedelic therapies ready to market after Australia became only the second country after Canada to approve their use to treat depression and PTSD.
Around Australia and the world, scientists, psychiatrists and CEOs are mapping out the potential of psychedelics. But not everyone’s on the same page.
Sam has a long-standing appreciation for psychedelics: that’s the reason he got into medicinal chemistry in the first place